Sintilimab Combined With Chemotherapy and Radiotherapy in Patients With Inoperable Pancreatic Cancer

Clinical trial NCT06050317 · RECRUITING

Trial details

NCT number: NCT06050317
Sponsor: Shandong Cancer Hospital and Institute
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Pancreas Cancer

Start date: 2023-08-18
Primary completion: 2025-08-18
Enrollment: 25

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.